ArticleBMC microbiology2025
Enhancement of carrimycin production in Streptomyces spiramyceticus 54-IA by the reporter-guided selection method with traditional mutagenesis.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Carrimycin, a new drug approved in recent years, is produced by recombinant Streptomyces spiramyceticus harboring a heterogeneous 4″-O-isovaleryltransferase gene (ist). The regulatory gene bsm42 plays a crucial role in activation of carrimycin biosynthesis, its high expression can improve the carrimycin production. The xylE-neo reporter cassette under control of the the two different lengths of bsm42 promoters, F1R and F2R, can be used to monitor the expression of bsm42 to screen carrimycin high-yield mutants treated with the composite mutagenesis of plasma and ultraviolet radiation. We found that 47% of the mutants selected based on the higher expression of reporter genes driven by bsm42 promoters showed improved carrimycin production, and the shorter promoter F2R was more effective than promoter F1R. The high-yield mutant F2R-15 was about 13 times higher than that of 54-IA strain, and its titer reached 1010 ± 30 µg/mL. A comparative analysis of the transcriptome profiles between the F2R-15 mutant and 54-IA strains revealed 158 significantly differentially expressed genes. The upregulated genes were associated with macrolide precursor biosynthesis, macrolide inactivation, antibiotic transporters, and oxidative phosphorylation, while the most downregulated genes were related to primary biosynthetic metabolites and other secondary metabolites. These results demonstrate that the reporter-guided selection method combined with traditional mutagenesis is an effective strategy for obtaining stable carrimycin high-yield mutants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.